Ypinga, Jan H. L.
Van Halteren, Angelika D.
Henderson, Emily J.
Bloem, Bastiaan R.
Smink, Agnes J.
Tenison, Emma
Munneke, Marten
Ben-Shlomo, Yoav
Darweesh, Sirwan K. L.
Funding for this research was provided by:
Gatsby Charitable Foundation (GAT3676)
Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships
National Parkinson Foundation
Article History
Received: 14 February 2021
Accepted: 1 July 2021
First Online: 23 July 2021
Declarations
:
: This study will be conducted according to the principles of the Declaration of Helsinki version 2013 and in accordance with the Good Clinical Practice (GCP) guidelines promulgated by the International Conference on Harmonization (ICH). The handling of personal data will comply with the General Data Protection Regulation 2018 (GDPR). The study has been reviewed by the ethics committee of the Radboud University Nijmegen Medical Centre on the basis of the Dutch Code of conduct for health research, the Dutch Code of conduct for responsible use, the Dutch Personal Data Protection Act and the Medical Treatment Agreement Act. The ethics committee has passed a positive judgment on the study.As part of the standard health insurance policy, all persons included in the claims database have agreed that their anonymised data can be used for analyses. For the questionnaire-based study persons with parkinsonism, carers and healthcare professionals can only participate if they have provided written informed consent.
: Not applicable.
: BRB currently serves as co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial of Practical Neurology and Digital Biomarkers, has received honoraria from serving on the scientific advisory board for Abbvie, Biogen and UCB, has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare and Bial, and has received research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, UCB, Abbvie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020 and the Parkinson Vereniging.EJH received funding from the National Institute of Health Technology (NIHR), the Gatsby Foundation and Parkinson’s UK; received fees for speaking and consultancy from Profile pharma Medicys and Luye; and received travel support from Bial Abbvie and Ever pharma.YBS is a recipient of a Radboud Excellence award. He has received research support from the UK Medical Research Council, Wellcome Trust, NIHR, Parkinson’s UK, Versus Arthritis, Gatsby Foundation, Dunhill Trust, and received a Radboud Excellence Award.SKLD was supported in part by a Parkinson's Foundation-Postdoctoral Fellowship (PF-FBS-2026). All other authors authors declare that they have no competing interests.